Semaglutide Inj — Class II drug recall D-0393-2026
Ongoing recall by New Life Pharma LLC, reported 2026-03-11, distributed in OH. Lack of Assurance of Sterility
| Recall number | D-0393-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | New Life Pharma LLC, Northvale, NJ, United States |
| Recall initiated | 2026-02-26 |
| Classified | 2026-03-17 |
| Reported by FDA | 2026-03-11 |
| Distributed | OH |
| Quantity | 2 vials |
| Reason classes | sterility |
| NDC | 84223-0001-06 |
| Lot numbers | 240903 |
| Expiration dates | 2026-09-30 |
Product
Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0393-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.